Opinion|Videos|November 22, 2024
R/R MM: Bispecifics in R/R MM: Key Takeaways
Panelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is promoted by the following;
- What are your current strategies for managing AEs (skin toxicities, dysgeusia, etc) seen with talquetamab?
- When do these toxicities typically appear, and how often do you see them in practice?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, AE management) in R/R MM.
- What clinical pearls can you share for fellow medical oncologists considering the use of bispecifics in R/R MM?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5